| Literature DB >> 9010039 |
C Bain1, Y Merrouche, I Puisieux, J Y Blay, S Negrier, V Bonadona, C Lasset, F Lanier, A Duc, L Gebuhrer, T Philip, M C Favrot.
Abstract
HLA phenotypes were characterized for 79 patients with metastatic renal cell carcinoma treated with interleukin 2 (IL-2). HLA-A32 was associated with a clinical response (P = 0.025). The frequency of HLA-A3 and/or A32 was higher among responders than non-responders (P = 0.008). Thus, these results suggest that, in vivo, IL-2 may enhance cellular-mediated immunity against a tumour antigen and that some MHC molecules are more efficient than others for endogenous tumour antigen presentation.Entities:
Mesh：
Substances：
Year: 1997 PMID： 9010039 PMCID： PMC2063266 DOI： 10.1038/bjc.1997.46
Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640